Download PDF
Thromb Haemost 2000; 83(06): 853-860
DOI: 10.1055/s-0037-1613933
Commentary
Schattauer GmbH

Enhanced Tissue Factor Pathway Activity and Fibrin Turnover in the Alveolar Compartment of Patients with Interstitial Lung Disease

A. Günther
2   Dept. of Internal Medicine, Justus-Liebig-University, Giessen
,
P. Mosavi
2   Dept. of Internal Medicine, Justus-Liebig-University, Giessen
,
C. Ruppert
2   Dept. of Internal Medicine, Justus-Liebig-University, Giessen
,
S. Heinemann
2   Dept. of Internal Medicine, Justus-Liebig-University, Giessen
,
B. Temmesfeld
2   Dept. of Internal Medicine, Justus-Liebig-University, Giessen
,
H. G. Velcovsky
2   Dept. of Internal Medicine, Justus-Liebig-University, Giessen
,
H. Morr
1   Klinik für Lungen- und Bronchialheilkunde, Greifenstein, Germany
,
F. Grimminger
2   Dept. of Internal Medicine, Justus-Liebig-University, Giessen
,
D. Walmrath
2   Dept. of Internal Medicine, Justus-Liebig-University, Giessen
,
W. Seeger
2   Dept. of Internal Medicine, Justus-Liebig-University, Giessen
› Author Affiliations
Further Information

Publication History

Received 02 December 1997

Accepted after resubmission 24 August 1999

Publication Date:
14 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Bronchoalveolar lavage fluids (BALF) from patients with hyper- sensitivity pneumonitis (HP; n = 35), idiopathic pulmonary fibrosis (IPF, n = 41) and sarcoidosis (SARC, n = 48) were investigated for alterations in the alveolar hemostatic balance. Healthy individuals (n = 21) served as Controls. Procoagulant activity (PCA), tissue factor (TF) activity and F VII activity were assessed by means of specific recalcification assays. The overall fibrinolytic activity (FA) was measured using the 125I-labeled fibrin plate assay. Fibrinopeptide A (FP-A), D-Dimer, plasminogen activators (PA) of the urokinase (u-PA) or tissue type (t-PA), PA-Inhibitor I (PAI-1) and α2-antiplasmin (α2-AP) were determined by ELISA technique. As compared to Controls, all groups with interstitial lung disease (ILD) displayed an increase in BALF PCA by approximately one order of magnitude, and this was ascribed to enhanced TF activity by >98%. Accordingly, F VII-activity was increased in all ILD groups, and elevated FP-A levels were noted. There was no significant difference in procoagulant activi- ties between the different ILD entities, but the increase in TF was significantly correlated with deterioration of lung compliance. Overall fibrinolytic activity did not significantly differ between ILD entities and Controls, although some reduction in IPF subjects was observed. Nevertheless, changes in the profile of the different pro- and anti- fibrinolytic compounds were noted. U-PA, but not t-PA levels were significantly reduced in all ILD groups. α2-AP was markedly elevated throughout, whereas PAI-1 levels were lowered. As a balance of enhanced procoagulant and sustained overall fibrinolytic activity, lavage D-dimer levels were elevated by more than one order of magnitude in all ILD patients. We conclude that the predominant alteration in alveolar hemostatic balance in all groups of ILD patients is an enhancement in TF factor pathway activity. Concomitantly, various compounds of the (anti-)fibrinolytic pathways present with altered concentrations, but the overall BALF fibrinolytic activity is largely unchanged. The net enhancement of fibrin turnover is significantly correlated with the decrease in lung compliance.

Abbreviations: α2-AP – α2-antiplasmin; ARDS – acute respiratory distress syndrome; BAL – bronchoalveolar lavage; BALF – BAL fluids; BSA – bovine serum albumin; FEV1 – forced expired volume within 1 s; FP-A – fibrinopeptide A; FVC – forced vital capacity; ILD – interstitial lung disease; IPF – idiopathic pulmonary fibrosis; HP – hypersensitivity pneumonitis; PAI-1 – plasminogen-activator-inhibitor-1; PBS – phosphate buffered saline; PCA – procoagulant activity; PL – phospholipid; PPQ – phospholipid-proteinquotient; SARC – sarcoidosis; t-PA – tissue-type plasminogen activator; u-PA – urokinase-type plasminogen activator

Keywords

Tissue factor - PAI-1 - u-PA - t-PA - interstitial lung disease (ILD)
 

  • References

  • 1 Idell S, James KK, Levin EG, Schwartz BS, Manchanda N, Maunder RJ, Martin TR, McLarty J, Fair DS. Local abnormalities in coagulation and fibrinolytyic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 1989; 84: 695-705.
    CrossrefPubMedGoogle Scholar
  • 2 Idell S, Koenig KB, Fair DS, Martin TR, McLarty J, Maunder RJ. Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. Am J Physiol 1991; 261: L240-L8.
    PubMedGoogle Scholar
  • 3 Seeger W, Hübel J, Klapettek K, Pison U, Obertacke U, Joka T, Roka L. Procoagulant activity in bronchoalveoar lavage of severely traumatized patients – relation to the development of acute respiratory distress. Thromb Res 1991; 91: 45-52.
    PubMedGoogle Scholar
  • 4 Chapman HA, Allen CL, Stone OL. Human alveolar macrophages synthe- zise factor VII in vitro. Possible role in interstitial lung disease. J Clin Invest 1985; 75: 2030-7.
    CrossrefPubMedGoogle Scholar
  • 5 McGee MP, Wallin R, Wheeler FB, Rothenberger H. Initiation of the extrinsic pathway of coagulation by human and rabbit alveolar macro- phages: a kinetic study. Blood 1989; 74: 1583-90.
    PubMedGoogle Scholar
  • 6 Gross TJ, Simon RH, Sitrin RG. Tissue factor procoagulant expression by rat alveolar epithelial cells. Am J Respir Cell Mol Biol 1992; 06: 397-403.
    CrossrefPubMedGoogle Scholar
  • 7 Gross TJ, Simon RH, Kelly CJ, Sitrin RG. Rat alveolar epithelial cells concomitantly express plasminogen activator inhibitor-1 and urokinase. Am J Physiol 1991; 260: L286-L95.
    PubMedGoogle Scholar
  • 8 Parton LA, Warbuton D, Laug WE. Plasminogen activator inhibitor type II production by rat type II pneumocytes in culture. Am J Respir Cell Mol Biol 1992; 06: 133-9.
    CrossrefPubMedGoogle Scholar
  • 9 Chapman HA, Yang X, Sailor LZ, Sugarbaker DJ. Developmental expres- sion of plasminogen activator inhibitor type I by human alveolar macropha- ges. Possible role in lung injury. J Immunol 1990; 145: 3398-405.
    PubMedGoogle Scholar
  • 10 Idell S, Zwieb C, Boggaram J, Holiday D, Johnson AR, Raghu G. Mecha- nisms of fibrin formation and lysis by human lung fibroblasts: influence of TGF-β and TNF-α. Am J Physiol 1992; 263: L487-L94.
    PubMedGoogle Scholar
  • 11 Idell S, James KK, Gillies C, Fair DS, Thrall RS. Abnormalities of path- ways of fibrin turnover in lung lavage of rats with oleic acid and bleomycin- induced lung injury support alveolar fibrin deposition. Am J Pathol 1989; 135: 387-99.
    PubMedGoogle Scholar
  • 12 Olman MA, Mackman N, Gladson CL, Moser KM, Loskutoff DJ. Changes in the procoagulant and fibrinolytic gene expression during bleomycin- induced lung injury in the mouse. J Clin Invest 1995; 96: 1621-30.
    CrossrefPubMedGoogle Scholar
  • 13 Perez RL, Roman J, Staton GW, Hunter RL. Extravascular coagulation and fibrinolysis in murine lung inflammation induced by the mycobacterial cord factor trehalose-6,6’-dimycolate. Am J Respir Crit Care Med 1994; 149: 510-8.
    CrossrefPubMedGoogle Scholar
  • 14 Sawaba M. Coagulation and fibrinolysis systems in bronchoalveolar lavage fluids in irradiated lung of rabbits. Nippon Kyobu Shikkan Gakkai Zasshi 1993; 31: 1515-21.
    PubMedGoogle Scholar
  • 15 Hasday JD, Bachwich PR, Lynch III JP, Sitrin RG. Procoagulant and plasminogen activator activities of bronchoalveolar fluid in patients with pulmonary sarcoidosis. Exp Lung Res 1988; 14: 261-78.
    CrossrefPubMedGoogle Scholar
  • 16 de Moerloose P, De Benedetti E, Nicod L, Vifian C, Reber G. Procoagulant activitiy in bronchoalveolar fluids: no relationship with tissue factor pathway inhibitor activity. Thromb Res 1992; 65: 507-18.
    CrossrefPubMedGoogle Scholar
  • 17 Nakstadt B, Lyberg T, Skjonsberg OH, Boye NP. Local activation of the coagulation and fibrinolysis systems in lung disease. Thromb Res 1990; 57: 827-38.
    CrossrefPubMedGoogle Scholar
  • 18 Kotani I, Sato A, Hayakaya H, Urano T, Takada Y, Takada A. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb. Res 1995; 77: 493-504.
    PubMedGoogle Scholar
  • 19 Robinson BWS. Production of plasminogen activator by alveolar macrophages in normal subjects and patients with interstitial lung disease. Thorax 1988; 43: 508-15.
    CrossrefPubMedGoogle Scholar
  • 20 Lohmeyer J, Friedrich J, Grimminger F, Maus U, Tenter R, Morr H, Velcovsky HG, Seeger W, Rosseau S. Expression of mucosa-related integrin αEβ7 on alveolar T cells in interstitial lung diseases. Clin Exp Immunol 1999; 116: 340-6.
    CrossrefPubMedGoogle Scholar
  • 21 Günther A, Kalinowski M, Elssner A, Seeger W. Clot embedded natural surfactant: kinetics of fibrinolysis and surface activity. Am J Physiol 1994; 267: L618-24.
    PubMedGoogle Scholar
  • 22 Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem 1959; 37: 911-7.
    PubMedGoogle Scholar
  • 23 Günther A, Siebert C, Schmidt R, Ziegler S, Grimminger F, Yabut M, Temmesfeld B, Walmrath D, Morr H, Seeger W. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med 1996; 153: 176-84.
    CrossrefPubMedGoogle Scholar
  • 24 Smith PK, Kohn RI, Hermannson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olso BJ, Klenk DC. Measurement of protein using bicinchoninic acid. Anal Biochem 1985; 150: 76-85.
    CrossrefPubMedGoogle Scholar
  • 25 Chapman HA, Bertozzi P, SailorL Z, Nusrat R. Alveolar macrophage urokinase receptors localize enzyme activity to the cell surface. Am J Physiol 1990; 259: L432-L8.
    CrossrefPubMedGoogle Scholar
  • 26 Sugiyama Y, Kasahara T, Mukaida N, Matsushima K, Kitamura S. Chemokines in bronchoalveolar lavage fluid in summer-type hypersensitivity pneumonitis. Eur Respir J 1995; 08: 1084-90.
    CrossrefPubMedGoogle Scholar
  • 27 Nakamura H, Fujishima S, Waki Y, Urano T, Sayama K, Sakamaki F, Terashima T, Soejima K, Tasaka S, Ishizaka A. Priming of alveolar macrophages for interleukin-8 production in patients with idiopathic lung fibrosis. Am J Respir Crit Care Med 1995; 152: 1579-86.
    CrossrefPubMedGoogle Scholar
  • 28 Walker C, Bauer W, Braun RK, Menz G, Braun P, Schwarz F, Hansel TT, Villiger B. Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. Am J Respir Crit Care Med 1994; 150: 1038-48.
    CrossrefPubMedGoogle Scholar
  • 29 Hernandez-Rodriguez NA, Chambrey AD, Harrison HK, Chambers RC, Gray AJ, Southcott AM, du Bois R, Black CM, Scully MF, Anulty RJ, Laurent GJ. Role of thrombin in pulmonary fibrosis. Lancet 1995; 346 8982 1071-3.
    CrossrefPubMedGoogle Scholar
  • 30 Gray AJ, Bishop JE, Reeves JT, Mecham RP, Laurent GJ. Partially degraded fibrin(ogen) stimulates fibroblast proliferation in vitro. Am J Respir Mol Cell Biol 1995; 12: 684-90.
    PubMedGoogle Scholar
  • 31 Yamada KM. Adhesive recognition sequences. J Biol Chem 1991; 266: 12809-12.
    PubMedGoogle Scholar
  • 32 Seeger W, Elssner A, Günther A, Krämer HJ, Kalinowski HO. Lung surfactant phospholipids associate with polymerizin fibrin: loss of surface activity. Am J Respir Cell Mol Biol 1993; 09: 213-20.
    CrossrefPubMedGoogle Scholar
  • 33 Günther A, Kalinowski M, Rosseau S, Seeger W. Surfactant incorporation markedly alters mechanical properties of a fibrin clot. Am J Respir Cell Mol Biol 1995; 13: 712-8.
    CrossrefPubMedGoogle Scholar
  • 34 Günther A, Kalinowski M, Elssner A, Seeger W. Clot-embedded natural surfactant: kinetics of fibrinolysis and surface activity. Am J Physiol 1994; 267: L618-L24.
    PubMedGoogle Scholar
  • 35 Ruf W, Edgington TE. Structural biology of tissue factor, the initiator of thrombogenesis in vivo. Faseb J 1994; 08: 385-90.
    CrossrefPubMedGoogle Scholar
  • 36 Günther A, Schmidt R, Nix F, Yabut-Perez M, Guth C, Rosseau S, Siebert C, Grimminger F, Morr H, Velcovsky HG, Seeger W. Surfactant abnormalities in idiopathic pulmonary fibrosis, hypersensitivity pneumonitis and sarcoidosis. Eur Respir J 1999; 14: 565-73.
    CrossrefPubMedGoogle Scholar
  • 37 McDonald JA. The yin and yang of fibrin in the airways. N Engl J Med 1992; 13: 929-31.
    PubMedGoogle Scholar
  • 38 Burkhardt A. Alveolitis and collapse in the pathogenesis of pulmonary fibrosis. Am Rev Respir Dis 1989; 140: 513-24.
    CrossrefPubMedGoogle Scholar